Respiratory allergy caused by house dust mites: What do we really know? - 03/07/15
, Allan Linneberg, MD, PhD b, Jörg Kleine-Tebbe, MD c, Frédéric De Blay, MD, PhD d, Dolores Hernandez Fernandez de Rojas, MD, PhD e, Johann Christian Virchow, MD, FRCP, FCCP f, Pascal Demoly, MD, PhD gAbstract |
The house dust mite (HDM) is a major perennial allergen source and a significant cause of allergic rhinitis and allergic asthma. However, awareness of the condition remains generally low. This review assesses the links between exposure to HDM, development of the allergic response, and pathologic consequences in patients with respiratory allergic diseases. We investigate the epidemiology of HDM allergy to explore the interaction between mites and human subjects at the population, individual, and molecular levels. Core and recent publications were identified by using “house dust mite” as a key search term to evaluate the current knowledge of HDM epidemiology and pathophysiology. Prevalence data for HDM allergen sensitization vary from 65 to 130 million persons in the general population worldwide to as many as 50% among asthmatic patients. Heterogeneity of populations, terminology, and end points in the literature confound estimates, indicating the need for greater standardization in epidemiologic research. Exposure to allergens depends on multiple ecological strata, including climate and mite microhabitats within the domestic environment, with the latter providing opportunity for intervention measures to reduce allergen load. Inhaled mite aeroallergens are unusually virulent: they are able to activate both the adaptive and innate immune responses, potentially offering new avenues for intervention. The role of HDM allergens is crucial in the development of allergic rhinitis and asthma, but the translation of silent sensitization into symptomatic disease is still incompletely understood. Improved understanding of HDMs, their allergens, and their microhabitats will enable development of more effective outcomes for patients with HDM allergy.
Le texte complet de cet article est disponible en PDF.Key words : Allergen, house dust mite, allergy, allergic asthma, allergic rhinitis, respiratory allergic disease, inflammation
Abbreviation used : HDM
Plan
| An educational grant for the development of this article was provided by ALK-Abelló. |
|
| Disclosure of potential conflict of interest: This study was funded by ALK-Abelló, Hørsholm, Denmark. M. A. Calderón has received compensation for board membership from ALK-Abelló and Stallergenes; has received consultancy fees from ALK-Abelló, Merck, Stallergenes, HAL Allergy, and Allergopharma, as well as payment for delivering lectures from ALK-Abelló, Merck, Stallergenes, and Allergopharma; and has received compensation for travel and other meeting-related expenses from ALK-Abelló, Merck, Stallergenes, and Allergopharma. A. Linneberg has received payment for delivering lectures from ALK-Abelló. J. Kleine-Tebbe has received or has grants pending from Circassia and has received compensation for board membership from ALK-Abelló, Novartis, and LETI, as well as consultancy fees from Merck, and has received payment for delivering lectures from Allergopharma, ALK-Abelló, Bencard, HAL Allergy, LETI Lofarma, Novartis, and Stallergenes. F. De Blay has received funding from Stallergenes and Chiesi; consultancy fees from Stallergenes, ALK-Abelló, Mundipharma, and Novartis; fees for participation in review activities from ALK-Abelló and Stallergenes; and compensation for board membership from Stallergenes, ALK-Abelló, Mundipharma, Novartis, and Same. J. C. Virchow has received consultancy fees from ALK-Abelló, as well as payment for delivering lectures. P. Demoly has received consultancy fees from ALK-Abelló, Circassia, Stallergenes, Allergopharma, Chiesi, Pierre Fabre Médicaments, and Ménarini and has received payment for delivering lectures from Ménarini, MSD, AstraZeneca, and GlaxoSmithKline. D. Hernandez Fernandez de Rojas declares no other relevant conflict of interest. |
Vol 136 - N° 1
P. 38-48 - juillet 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
